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decreased detection of the anaphylatoxin C5a (a marker of com-
plement activation located downstream in the complement cas-
cade) in CFT supernatants from the same experiments (Fig. 1b).
Our in vitro results suggest that patients with BP may benefit
from off-label LMWH use. Inhibiting ongoing complement
fixation and C5a liberation by LMWH may improve skin dis-
ease, as suggested in part by BP disease models employing C5a
receptor-deficient mice.9 Such therapy might also help prevent
coagulation-related complications in BP,2,10 but the risk vs.
benefit in this regard would have to be carefully studied.
LMWHs are generally considered safe therapeutics, although
long-term side-effects do include osteoporosis, which is also a
side-effect of standard BP therapy with corticosteroids.
One limitation of our in vitro study may be the rather supra-
physiological concentrations of TS used, but at the same time,
a high-titre pool of BP sera was used for CFT, resulting in
strong BMZ autoantibody binding. Given that clinically overt
disease is seen at considerably lower titres of circulating
autoantibodies in patients with BP and that the in vitro CFT also
works with highly diluted BP sera by extending times of incu-
bation with the fresh complement source (data not shown),
we find it conceivable that lower, more physiological TS doses
may also be effective, as already suggested in patients with
complement-mediated renal disease.7 In addition, there may
be LMWHs other than TS that could inhibit complement bet-
ter at similar or even lower doses.
In summary, we suggest that patients with BP with comple-
ment deposits at the BMZ may benefit from LMWH adminis-
tration. Positive effects of LMWH may also be observed in
other complement-fixing diseases such as mucous membrane
pemphigoid, epidermolysis bullosa acquisita, autoantibody-
mediated forms of glomerulonephritis and C3 glomeru-
lonephritis. To confirm conclusively the therapeutic potential
hypothesized in this report, additional in vivo studies employ-
ing animal models and randomized controlled trials in patients
are warranted.
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Surveillance for familial melanoma:
recommendations from a national
centre of expertise
DOI: 10.1111/bjd.17767
DEAR EDITOR, An estimated 10% of patients diagnosed with
melanoma have a positive family history for this cutaneous
malignancy.1 Familial melanoma is arbitrarily defined as the
occurrence of three or more melanomas in multiple members
of a family, at least two of which are diagnosed in first-degree
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relatives. The pedigrees of these families are compatible with
an autosomal dominant mode of inheritance. In a subset of
families, clustering is caused by polygenic inheritance or
shared ultraviolet radiation exposure patterns among members.
The genetic basis of familial melanoma can currently be estab-
lished in less than half of cases and differs within populations.
The term hereditary melanoma is commonly used when the
causative pathogenic gene variant in a family has been identi-
fied. Most cases of hereditary melanoma are caused by patho-
genic variants in the CDKN2A gene, which encodes the p16
and p14 tumour suppressor proteins. Carriers of pathogenic
variants in this gene are also at risk of developing pancreatic
cancer. For carriers of the p16-Leiden variant in CDKN2A (19-
base pair deletion in exon 2) the lifetime risk of pancreatic
cancer amounts to 18%, but for other inactivating CDKN2A
variants this risk may be less.2
In recent years more melanoma susceptibility genes have
been identified, each associated with increased risk of various
tumour types in addition to melanoma.1 Several more candi-
date genes have been proposed and more await discovery.
Surveillance of individuals carrying melanoma susceptibility
gene variants increases early detection and treatment out-
come.3 However, it can be difficult, in particular for dermatol-
ogists who encounter this condition infrequently, to
determine which members of a family should undergo peri-
odic skin examination and other oncological screening proce-
dures. There is a paucity of clinical evidence supporting the
benefit of surveillance in genetically defined familial mela-
noma subgroups. Here we present recommendations of the
centre of expertise for familial melanoma in the Netherlands,
based on our clinical experience and scarce evidence.
We refer members of families who meet the criteria for a
diagnosis of familial melanoma to a clinical geneticist for
counselling and genetic testing from the age of 18 years.
Preferably genetic tests are performed on DNA from a family
member diagnosed with invasive melanoma. Additionally, we
recommend referral of families where two first-degree rela-
tives are diagnosed with melanoma, and families where mela-
noma and pancreatic cancer are diagnosed. We also
recommend clinical genetic consultation for patients with
three or more melanomas, patients with melanoma diagnosed
before the age of 18 years, patients with multiple BAP1-defi-
cient melanocytic naevi and patients with a combination of
melanoma and pancreatic cancer or uveal melanoma.
All individuals at increased risk of melanoma receive oral
and written instructions on self-examination of the skin and
on sun-protective behaviour. Dermatological surveillance con-
sists of total skin examination with use of dermoscopy and
total body photography. Patients are encouraged to visit our
clinic if suspicious pigmented skin lesions are noticed, and to
abstain from smoking.
Currently we offer high-risk patients genetic testing for muta-
tions in eight established melanoma susceptibility genes using a
custom-designed targeted gene panel. For carriers of pathogenic
variants in these genes and their first-degree relatives the pro-
posed dermatological and oncological surveillance schedules are
presented in Table 1. To carriers of a pathogenic variant in the
CDKN2A, CDK4 or TERT genes we recommend biannual skin exam-
ination. In our centre, first-degree relatives of carriers of these
variants undergo annual skin examination from the age of 12
years and second-degree relatives from the age of 20 years.3,4
To carriers of pathogenic variants in the BAP1, MITF, POT1,
TERF2IP or ACD genes and their first-degree relatives we rec-
ommend annual skin examinations, as melanoma risk for car-
riers of these gene variants is lower or remains to be
determined. To patients and their first-degree relatives with
familial melanoma where no DNA testing is performed, where
no pathogenic gene variant is detected or where the functional
Table 1 Surveillance recommendations for familial and hereditary melanoma1–4,6–8
Gene Established associated tumour types Carrier First-degree relative
CDKN2A Pancreatic, head and neck cancer,
basal cell carcinoma
Skin examination: biannual, from age 12
MRI/EUS pancreas:a annual, from age 45
Skin examination: annual, from age 12a
CDK4 – Skin examination: biannual, from age 12 Skin examination: annual, from age 12
BAP1 Uveal melanoma, mesothelioma,
renal cancer, cholangiocarcinoma,
meningioma, basal cell carcinoma
Skin examination: annual, from age 20
Eye examination: annual, from age 15
Ultrasound abdomen: biennial (alternating),
from age 30
X-ray thorax, MRI abdomen: biennial
(alternating), from age 30
Skin examination: annual, from age 20
Eye examination: annual, from age 15
MITF Renal, pancreatic cancer Skin examination: annual, from age 12 Skin examination: annual, from age 12
TERT Bladder, breast, endometrial,
lung, ovarian, renal cancer
Skin examination: biannual, from age 12 Skin examination: annual, from age 12
POT1 Glioma, chronic lymphocytic leukaemia Skin examination: annual, from age 12 Skin examination: annual, from age 12
TERF2IP – Skin examination: annual, from age 12 Skin examination: annual, from age 12
ACD – Skin examination: annual, from age 12 Skin examination: annual, from age 12
No DNA test performed, or no pathogenic
variant detected
Skin examination: annual, from age 12 Skin examination: annual, from age 12
MRI, magnetic resonance imaging; EUS, endoscopic ultrasound. aScreening for pancreatic cancer is recommended to carriers of pathogenic
variants located in exon 1a, 2 or 3 of the CDKN2A gene, affecting the p16 transcript.
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consequence of the identified variant is uncertain, we recom-
mend annual skin examination. Identified gene variants classi-
fied as uncertain or likely not pathogenic (IARC system class
1, 2 or 3) we consider as not pathogenic.5
The proposed dermatological and oncological surveillance
schedules are to be considered as a basal frequency. Diagnosis
of multiple melanomas, presence of dysplastic naevi, and
other factors, could prompt more frequent examinations.
Decisions on surveillance and examination frequency should
be made on an individual basis by weighing benefits against
psychological burden and potential harm from diagnostic pro-
cedures. Current and future studies on the absolute risk of var-
ious malignancies in carriers of variants in the recently
discovered melanoma susceptibility genes will inform these
decisions and may lead to modifications of the proposed
surveillance schedules and diagnostic procedures. We hope
these recommendations will help to improve management of
patients with familial and hereditary melanoma.
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Photoacoustic imaging as an innovative
technique for the exploration of blue rubber
bleb naevus
DOI: 10.1111/bjd.17765
DEAR EDITOR, Blue rubber bleb naevus syndrome (BRBN, Bean
syndrome) is a rare vascular malformation (VM) characterized
by multiple cutaneous and mucous venous defects dissemi-
nated throughout the body. An infringement of mucous mem-
branes is possible with potential complications such as
anaemia or haemorrhage.1 Photoacoustic imaging (PAI) is an
emerging technology combining the most compelling features
of optical imaging and ultrasound, providing both high opti-
cal contrast and high ultrasound resolution at depth in living
organisms.2 PAI offers great potential for noninvasive explo-
ration of tissue, leveraging differences in the optical absorp-
tion of underlying tissue components. In particular, oxy- and
deoxyhaemoglobin are endogenous absorbers that exhibit
specific photoacoustic signals. By using several wavelengths of
laser light, relative concentrations of these specific compounds
can be determined, providing mapping of total haemoglobin
content (HbT) and tissue oxygen saturation (StO2) in several
tissue layers at submillimetre resolution.3,4 PAI could be of
prime importance for the exploration of VM.
This study reports the use of this new imaging modality,
nonionizing and contrast agent free, to monitor the HbT and
StO2 of several BRBN lesions on a 36-year-old patient. The
patient presented with BRBN with multiple lesions of the
arms, lower limbs and trunk. Doppler ultrasound confirmed
the multiple extratruncal low-flow vascular lesions. Ultrasound
(B-mode) and PAI were performed using the Vevo LAZR-X
system (FUJIFILM VisualSonics, Inc., Toronto, ON, Canada)
with a 21-MHz transducer. Three dysplastic sites were scanned
– on the left lower limb (Fig. 1a), the left heel and the right
forearm (images available on request) – as well as control
zones (dermal tissue). The oxyhaemoglobin multispectral PAI
mode (750 nm, 850 nm) was used for the evaluation of HbT
and StO2.
Our results shown that the VM zone on the lower limb
(Fig. 1) displayed a very strong photoacoustic signal
(Fig. 1c), showing blood accumulation in the lesion area.
PAI-derived quantitative values demonstrated significantly
higher values of both HbT and StO2 compared with the con-
tralateral zone (9 21 for HbT and 9 16 for StO2). In the
same way, the VM on the left heel exhibited a clear but
heterogeneous photoacoustic signal, illustrating blood accu-
mulation but restricted to a partial zone of the lesion. Quan-
titative analyses demonstrated higher HbT and StO2 than in
the contralateral zone (9 18 for HbT and 9 15 for StO2).
The PAI results thus illustrated blood accumulation in these
two sites, which appeared to be highly oxygenated. Images
from other lesions and quantification of HbT and StO2 mea-
surements are available on request.
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